High prevalence of hypothyroidism and hyperthyroidism to escalate demand for endocrine testing

 

endocrine testing

The endocrine system consists of an intricate network of glandular structures that secreted hormones that regulate many important body processes, such as the body's capability to convert fats into energy which powers living tissues and organs, and the rate at which cells are replaced after injury or disease. Many diseases have been linked to endocrine dysfunctions and include breast cancer, diabetes, obesity, Alzheimer's, and multiple sclerosis. Endocrine disorders can be caused by exposure to toxins such as cigarette smoke, certain chemicals and pesticides, stress, infection, hormones, drugs, and radiation. Tumors can also cause endocrine problems as well, although very few tumors have been found to contain hormones and/or endocrine stimulating agents. Endocrine dysfunctions can cause hormonal imbalance, which can affect the pituitary gland which directly controls hormone production

The rising prevalence of endocrine disorders such as hyperthyroidism is primarily driving the growth of endocrine testing market. Moreover, the growing geriatric population is another key factor increasing the prevalence of hyperthyroidism which in turn augmenting the growth of endocrine testing market. According to the World Health Organization, by 2050, the world’s population aged 60 years and older is expected to total 2 billion, up from 900 million in 2015. By 2050, there will be almost this many (120 million) living in China alone, and 434 million people in this age group worldwide. By 2050, 80% of all older people will live in low- and middle-income countries. Also, growing advancement in the technologies such as easy-to-operate test kits which are user-friendly and cost-effective is again further projected to foster the market growth.

North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of hypothyroidism and hyperthyroidism in the region. According to the U.S. Department of Health and Human Services, about 4.6 percent of the U.S. population ages 12 and older has hypothyroidism, although most cases are mild. That’s almost 5 people out of 100.

Key Developments:

  1. In December 2019, the professional associations France Chimie, the FEBEA and the Fondation de la Maison de la Chimie, in partnership with the French Ministry of Ecological and Solidarity Transition, announce the creation of PEPPER, a public-private platform designed to develop research on the identification of endocrine disruptors

  2. In November 2020, Institut national de la recherche scientifique (INRS) announce the creation of the Intersectoral Centre for Endocrine Disruptors Analysis (ICEDA), a new center devoted to the analysis of endocrine disruptors.

Comments

Popular posts from this blog

Increasing Initiatives to Digitalize the Healthcare Sector Is Expected To Boost Demand for Electronic Medical Records

Potential of Indian Tourism

Nanocoatings are viable and give security from different ecological components